**Abstract**

***Background:*** Recently, modulation of NMDA neurotransmission has become an attractive approach for discovering novel treatment for schizophrenia, particularly cognitive impairment. Sodium benzoate, a D-amino acid oxidase (DAAO) inhibitor, and sarcosine, a glycine transporter I (GlyT-1) inhibitor, both can enhance NMDA receptor-mediated neurotransmission. We proposed that combination of inhibiters DAAO and GlyT-1 may be more effective than inhibition of either in improving the cognitive functioning of schizophrenia patients.

***Methods:*** This 12-week, double-blind, randomized, placebo-controlled trial compared adjunctive benzoate (1 g/day) plus sarcosine (2 g/day) vs. sarcosine (2 g/day) for clinical symptoms, cognitive function, and global functioning of chronic schizophrenia patients who have been stabilized with various second-generation antipsychotics. Participants were measured with the Positive and Negative Syndrome Scale and the Global Assessment of Functioning Scale every 3 weeks. Seven cognitive domains, recommended by the Measurement and Treatment Research to Improve Cognition in Schizophrenia Committee, were measured at weeks 0 and 12.

***Results:*** Combination of both NMDA-enhancing agents, rather than sarcosine alone or placebo, improved global functioning and the global composite score of all 7 cognitive domains of patients with schizophrenia while their clinical symptoms remained unimproved.

***Discussion:*** Our previous study showed that add-on benzoate improved cognitive function and clinical symptoms of chronic schizophrenia patients who had been stabilized at haloperidol or risperidone. Whether the cognitive improvement was secondary to symptom reduction remained uncertain. The findings of the current study plus the previous study suggest that NMDA-enhancement therapy can improve the cognitive function of patients with schizophrenia, supporting the pro-cognitive effect can be primary no matter whether clinical symptoms improve or not.
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